Antibody-based Proteomics: Fast-tracking Molecular Diagnostics in Oncology

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2010 Aug 20

PMID 20720569

Citations 71

Authors

Donal J Brennan

Darran P OConnor

Elton Rexhepaj

Fredrik Ponten

William M Gallagher

Affiliations

Soon will be listed here.

Abstract

The effective implementation of personalized cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Antibody-based proteomics occupies a pivotal space in the cancer biomarker discovery and validation pipeline, facilitating the high-throughput evaluation of candidate markers. Although the clinical utility of these emerging technologies remains to be established, the traditional use of antibodies as affinity reagents in clinical diagnostic and predictive assays suggests that the rapid translation of such approaches is an achievable goal. Furthermore, in combination with, or as alternatives to, genomic and transcriptomic methods for patient stratification, antibody-based proteomics approaches offer the promise of additional insight into cancer disease states. In this Review, we discuss the current status of antibody-based proteomics and its contribution to the development of new assays that are crucial for the realization of individualized cancer therapy.

Citing Articles

Unveiling the power of proteomics in advancing tropical animal health and production.

Adnane M, de Almeida A, Chapwanya A Trop Anim Health Prod. 2024; 56(5):182.

PMID: 38825622 DOI: 10.1007/s11250-024-04037-4.

Single-cell multi-omics in the study of digestive system cancers.

Zhou S, Lin N, Yu L, Su X, Liu Z, Yu X Comput Struct Biotechnol J. 2024; 23:431-445.

PMID: 38223343 PMC: 10787224. DOI: 10.1016/j.csbj.2023.12.007.

Improving de novo protein binder design with deep learning.

Bennett N, Coventry B, Goreshnik I, Huang B, Allen A, Vafeados D Nat Commun. 2023; 14(1):2625.

PMID: 37149653 PMC: 10163288. DOI: 10.1038/s41467-023-38328-5.

High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients.

Marino D, Pizzi M, Kotova I, Schmidt R, Schroder C, Guzzardo V Cancers (Basel). 2022; 14(2).

PMID: 35053500 PMC: 8774128. DOI: 10.3390/cancers14020338.

Towards Building a Quantitative Proteomics Toolbox in Precision Medicine: A Mini-Review.

Correa Rojo A, Heylen D, Aerts J, Thas O, Hooyberghs J, Ertaylan G Front Physiol. 2021; 12:723510.

PMID: 34512391 PMC: 8427610. DOI: 10.3389/fphys.2021.723510.

References

Anderson N, Polanski M, Pieper R, Gatlin T, Tirumalai R, Conrads T . The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics. 2004; 3(4):311-26. DOI: 10.1074/mcp.M300127-MCP200. View

Uemura N, Nakanishi Y, Kato H, Nagino M, Hirohashi S, Kondo T . Antibody-based proteomics for esophageal cancer: Identification of proteins in the nuclear factor-kappaB pathway and mitotic checkpoint. Cancer Sci. 2009; 100(9):1612-22. PMC: 11159346. DOI: 10.1111/j.1349-7006.2009.01230.x. View

Kosari F, Munz J, Dilara Savci-Heijink C, Spiro C, Klee E, Kube D . Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res. 2008; 14(6):1734-43. DOI: 10.1158/1078-0432.CCR-07-1494. View

Glas A, Floore A, Delahaye L, Witteveen A, Pover R, Bakx N . Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics. 2006; 7:278. PMC: 1636049. DOI: 10.1186/1471-2164-7-278. View

Carlsson A, Wingren C, Ingvarsson J, Ellmark P, Baldertorp B, Ferno M . Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur J Cancer. 2008; 44(3):472-80. DOI: 10.1016/j.ejca.2007.11.025. View

Giltnane J, Ryden L, Cregger M, Bendahl P, Jirstrom K, Rimm D . Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol. 2007; 25(21):3007-14. DOI: 10.1200/JCO.2006.08.9938. View

Hanash S . Disease proteomics. Nature. 2003; 422(6928):226-32. DOI: 10.1038/nature01514. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Sawyers C . Shifting paradigms: the seeds of oncogene addiction. Nat Med. 2009; 15(10):1158-61. DOI: 10.1038/nm1009-1158. View

10.

Mcdermott D, Sosman J, Gonzalez R, Hodi F, Linette G, Richards J . Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008; 26(13):2178-85. DOI: 10.1200/JCO.2007.14.8288. View

11.

Weinstein I . Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297(5578):63-4. DOI: 10.1126/science.1073096. View

12.

Fan C, Oh D, Wessels L, Weigelt B, Nuyten D, Nobel A . Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006; 355(6):560-9. DOI: 10.1056/NEJMoa052933. View

13.

Taussig M, Stoevesandt O, Borrebaeck C, Bradbury A, Cahill D, Cambillau C . ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. Nat Methods. 2006; 4(1):13-7. DOI: 10.1038/nmeth0107-13. View

14.

Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks T, Hewitt S . Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res. 2009; 16(1):240-8. PMC: 7581274. DOI: 10.1158/1078-0432.CCR-09-0986. View

15.

Fernandez D, Bhargava R, Hewitt S, Levin I . Infrared spectroscopic imaging for histopathologic recognition. Nat Biotechnol. 2005; 23(4):469-74. DOI: 10.1038/nbt1080. View

16.

Prabhakar U, Eirikis E, Reddy M, Silvestro E, Spitz S, Pendley 2nd C . Validation and comparative analysis of a multiplexed assay for the simultaneous quantitative measurement of Th1/Th2 cytokines in human serum and human peripheral blood mononuclear cell culture supernatants. J Immunol Methods. 2004; 291(1-2):27-38. DOI: 10.1016/j.jim.2004.04.018. View

17.

Whiteaker J, Zhao L, Zhang H, Feng L, Piening B, Anderson L . Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem. 2007; 362(1):44-54. PMC: 1852426. DOI: 10.1016/j.ab.2006.12.023. View

18.

Brennan D, Brandstedt J, Rexhepaj E, Foley M, Ponten F, Uhlen M . Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. BMC Cancer. 2010; 10:125. PMC: 3087316. DOI: 10.1186/1471-2407-10-125. View

19.

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

20.

Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, Hanna J . Antibody validation. Biotechniques. 2010; 48(3):197-209. PMC: 3891910. DOI: 10.2144/000113382. View